The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CYCN | -35.9% | -96.66% | -49.33% | -99% |
| S&P | +18.54% | +92.9% | +14.04% | +139% |
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
A second midstage failure is hurting the biotech's stock price today.
A double clinical trial failure sends the biotech’s shares down.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.09M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $9.34M | 49.9% |
| Market Cap / Employee | $9.34M | 0.0% |
| Employees | 1 | 0.0% |
| Net Income | -$0.32M | 75.5% |
| EBITDA | -$1.67M | -20.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.01M | -34.5% |
| Accounts Receivable | $0.53M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -20.03% | 83.8% |
| Return On Invested Capital | -101.35% | 7.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.50M | 54.5% |
| Operating Free Cash Flow | -$0.50M | 54.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.74 | 0.99 | 0.72 | 1.01 | 75.09% |
| Price to Sales | 33.72 | 4.10 | 3.07 | 4.11 | - |
| Price to Tangible Book Value | 0.74 | 0.99 | 0.72 | 1.01 | 75.09% |
| Enterprise Value to EBITDA | -3.25 | 9.89 | -1.89 | -3.55 | 314.27% |
| Return on Equity | -50.1% | -30.4% | -31.5% | -22.4% | -85.07% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
